The CDC’s 2026 antibiotic resistance report elevates drug-resistant gonorrhea to urgent threat status, signaling that Neisseria gonorrhoeae now joins only three other infections requiring aggressive national action to prevent untreatable spread.
The move reflects surveillance data showing that 55.4 percent of U.S. isolates tested in 2023 displayed resistance or reduced susceptibility to at least one antibiotic, though resistance to the current last-line injectable, ceftriaxone, remains rare at 0.1 percent.
The bacterium has sequentially defeated penicillin, tetracycline, and fluoroquinolones like ciprofloxacin since the 1930s. Current dual-therapy guidelines — ceftriaxone plus azithromycin — were abandoned in 2021 after azithromycin resistance climbed, leaving ceftriaxone monotherapy as the sole recommended first-line regimen in the United States.
- Gonorrhea is still curable today, but the bacteria are evolving faster than new drugs are approved.
- Standard treatment is now a single shot of ceftriaxone; pills alone are no longer reliable.
- Condoms and routine screening remain the most effective personal defenses against resistant strains.
The FDA approved zoliflodacin and gepotidacin in late 2024, marking the first novel antibiotic classes for gonorrhea in over three decades. Zoliflodacin, a spiropyrimidinetrione, inhibits bacterial type II topoisomerase at a site distinct from fluoroquinolones. Gepotidacin, a triazaacenaphthylene, blocks DNA gyrase and topoisomerase IV via a novel binding mechanism. Both are oral, single-dose regimens.
Phase 3 trials demonstrated non-inferiority to ceftriaxone for urogenital infections.
| Drug | Class | Route | Urogenital Cure Rate (Phase 3) | Pharyngeal Efficacy | Key Adverse Events (≥2%) |
|---|---|---|---|---|---|
| Ceftriaxone | Third-gen cephalosporin | IM injection | High | Injection site pain, hypersensitivity | |
| Zoliflodacin | Spiropyrimidinetrione | Oral | Insufficient data | GI upset, dizziness, elevated transaminases | |
| Gepotidacin | Triazaacenaphthylene | Oral | Insufficient data | GI upset, headache, vaginitis |
Funding for zoliflodacin development came through a public-private partnership between the Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics, later acquired by Innoviva. Gepotidacin was developed by GSK with support from the Biomedical Advanced Research and Development Authority (BARDA). Both approvals utilized the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), which permits smaller trials for serious infections with unmet need.
The WHO’s Gonococcal Antimicrobial Surveillance Programme (GASP) covers 12 countries across five regions, but data from high-burden regions in sub-Saharan Africa and parts of Asia remain sparse. A 2024 WHO report documented ceftriaxone-resistant strains with mosaic penA alleles in multiple European nations and China, though sustained community transmission has not been confirmed.
The European Medicines Agency (EMA) has not yet authorized zoliflodacin or gepotidacin, leaving European clinicians reliant on ceftriaxone and, in some countries, spectinomycin where available.
The CDC estimates 787,000 resistant infections occurred in the U.S. in 2023. Surveillance data for 2024, released this fall, showed chlamydia, gonorrhea, and syphilis rates declining slightly for the first time in a decade — a trend officials attribute partly to expanded screening but caution may reflect pandemic-era reporting artifacts.
“The new drugs buy us time, but they are not a permanent fix,” said Dr. Teodora Wi, WHO medical officer for STIs, in a statement to ashasexualhealth.org. “Without a vaccine and rational use policies, resistance to these agents will emerge, too.”
Research into meningococcal B vaccines offering cross-protection against gonorrhea continues; observational studies in New Zealand, Canada, and the U.S. suggest 30–40 percent effectiveness against infection, though no gonorrhea-specific vaccine has reached Phase 3 trials.
- CDC. Antibiotic Resistance Threats Report 2026.
- Global Antibiotic Research and Development Partnership. Zoliflodacin Phase 3 Trial Results.
- GSK. Gepotidacin Phase 3 Clinical Trial Data.
- World Health Organization. Gonococcal Antimicrobial Surveillance Programme Report 2024.
- CDC. Sexually Transmitted Disease Surveillance 2024.